Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880493 | 0.91 | ESR1 (0.62) | ESR1ESR2 | |
| SCHEMBL6051146 | 0.82 | ESR1 (0.64) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL8425147 | 0.82 | ESR1 (0.72) | ESR1ESR2 | |
| SCHEMBL7943653 | 0.81 | ESR1 (1.00) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL8429229 | 0.81 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL9153745 | 0.80 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL9152189 | 0.79 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL30076531 | 0.78 | ESR1 (0.89) | ESR1ESR2 | |
| SCHEMBL7938790 | 0.76 | ESR1 (0.82) | ESR1ESR2 | |
| SCHEMBL7056486 | 0.75 | ESR1 (0.91) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618971-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7585866-B2 | Modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; cancer; chronic myelogic leukemia | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2009-09-08 | — | — | US | disclosed |
| US-7547695-B2 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-7329762-B2 | Prodrugs of mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20080027058-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070099910-A1 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20060134767-A1 | Mitotic kinesin binding site | MERCK & CO., INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060135594-A1 | Prodrugs of mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-06-22 | — | — | US | disclosed |
| US-20060069105-A1 | Protein tyrosine kinase inhibitors | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2006-03-30 | — | — | US | disclosed |
| US-20050182256-A1 | 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; antiproliferative | MERCK & CO., INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050171122-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-08-04 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135594-A1 | Prodrugs of mitotic kinesin inhibitors | KIF2C, KIF5B, KIFC1 | ESR1 3814/4885ESR2 4084/4885 |
| US-20080027058-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF23 | ESR1 4291/4885ESR2 4125/4885 |
| US-20070099910-A1 | Pyridopyrimidinones | TIE1, FER, FLT1 | ESR1 864/4885ESR2 1109/4885 |
| US-20060069105-A1 | Protein tyrosine kinase inhibitors | ABL1, ERBB2, SRC | ESR1 1733/4885ESR2 1413/4885 |
| US-20050171122-A1 | Mitotic kinesin inhibitors | KIF5B, KIFC1, KIF2C | ESR1 4167/4885ESR2 4280/4885 |
| US-20050182256-A1 | 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; antiproliferative | PLK1, AKT2, SKP2 | ESR1 3145/4885ESR2 2005/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | ESR1 2505/4885ESR2 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.